Myeloid drugs rarely prove immune conversion in solid tumors
A 2026 narrative review finds that most myeloid-directed cancer programs show target activity without proving immune conversion and proposes a ...
A 2026 narrative review finds that most myeloid-directed cancer programs show target activity without proving immune conversion and proposes a ...
Researchers have replaced the toxic components of a macrophage-directed immunotherapy for Ewing sarcoma with cyclophosphamide and the erythrocyte-sparing antibody lemzoparlimab, ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine